2021 ESA立场声明:成人原发性甲状旁腺功能亢进的手术治疗和术后随访

2021-12-19 澳大利亚内分泌学会 Clin Endocrinol (Oxf)

2021年12月,澳大利亚内分泌学会(ESA)联合澳大利亚&新西兰内分泌外科医生协会以及骨矿学会共同发布了成人原发性甲状旁腺功能亢进的手术治疗和术后随访共识声明。

中文标题:

2021 ESA立场声明:成人原发性甲状旁腺功能亢进的手术治疗和术后随访

英文标题:

Primary hyperparathyroidism in adults-(Part II) surgical management and postoperative follow-up: Position statement of the Endocrine Society of Australia, The Australian & New Zealand Endocrine Surgeons, and The Australian & New Zealand Bon

发布机构:

澳大利亚内分泌学会

发布日期:

2021-12-19

简要介绍:

2021年12月,澳大利亚内分泌学会(ESA)联合澳大利亚&新西兰内分泌外科医生协会以及骨矿学会共同发布了成人原发性甲状旁腺功能亢进的手术治疗和术后随访共识声明。本文主要针对成人原发性甲状旁腺功能亢进的手术治疗和术后随访提供指导建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 ESA立场声明:成人原发性甲状旁腺功能亢进的手术治疗和术后随访.pdf)] GetToolGuiderByIdResponse(projectId=1, id=4f0d41c002298e49, title=2021 ESA立场声明:成人原发性甲状旁腺功能亢进的手术治疗和术后随访, enTitle=Primary hyperparathyroidism in adults-(Part II) surgical management and postoperative follow-up: Position statement of the Endocrine Society of Australia, The Australian & New Zealand Endocrine Surgeons, and The Australian & New Zealand Bon, guiderFrom=Clin Endocrinol (Oxf), authorId=0, author=, summary=2021年12月,澳大利亚内分泌学会(ESA)联合澳大利亚&新西兰内分泌外科医生协会以及骨矿学会共同发布了成人原发性甲状旁腺功能亢进的手术治疗和术后随访共识声明。, cover=https://img.medsci.cn/20211222/1640166595009_1608702.jpg, journalId=0, articlesId=null, associationId=1266, associationName=澳大利亚内分泌学会, associationIntro=, copyright=0, guiderPublishedTime=Sun Dec 19 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年12月,澳大利亚内分泌学会(ESA)联合澳大利亚&amp;新西兰内分泌外科医生协会以及骨矿学会共同发布了成人原发性甲状旁腺功能亢进的手术治疗和术后随访共识声明。本文主要针对成人原发性甲状旁腺功能亢进的手术治疗和术后随访提供指导建议。</span></p>, tagList=[TagDto(tagId=736, tagName=甲状腺), TagDto(tagId=100875, tagName=原发性甲状旁腺功能亢进)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=100875, guiderKeyword=原发性甲状旁腺功能亢进, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=1750, appHits=32, showAppHits=0, pcHits=224, showPcHits=1718, likes=0, shares=4, comments=1, approvalStatus=1, publishedTime=Wed Dec 22 17:46:56 CST 2021, publishedTimeString=2021-12-19, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Wed Dec 22 17:54:45 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Tue Jan 02 21:49:19 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ESA立场声明:成人原发性甲状旁腺功能亢进的手术治疗和术后随访.pdf)])
2021 ESA立场声明:成人原发性甲状旁腺功能亢进的手术治疗和术后随访.pdf
下载请点击:
评论区 (1)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1185448, encodeId=a58111854484c, content=👍👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:37:20 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-01-18 ms6000000807686529

    👍👍👍

    0